



Marksans Pharma Ltd.

The National Stock Exchange of India Ltd

Listing Department,
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (E), Mumbai- 400 051

BSE Limited

Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

18th October, 2016

PRESS RELEASE

Marksans Pharma Limited announces USFDA approval for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg (ANDA 204948)

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1 mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

Paricalcitol is a Synthetic Vitamin D analog. Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol is used to treat or prevent hyper parathyroidism (overactive para thyroid gland). It has been used to reduce parathyroid hormone level.

Thanking you

Yours faithfully,
For **Marksans Pharma Limited**

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com